Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
DBV TechnologiesS. A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy.
It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV TechnologiesS. A. was incorporated in 2002 and is headquartered in Châtillon, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 25 | -0.21 Decreased by -265.92% | -0.21 Decreased by -1.24% |
| Nov 7, 24 | -1.49 Decreased by -1.76 K% | -1.64 Increased by +9.23% |
| Jul 30, 24 | -0.34 Decreased by -183.33% | -0.45 Increased by +24.44% |
| May 9, 24 | -0.56 Decreased by -154.55% | -0.21 Decreased by -166.67% |
| Mar 7, 24 | -0.06 Increased by +86.80% | -0.23 Increased by +74.74% |
| Oct 31, 23 | -0.08 Increased by +55.56% | -0.22 Increased by +63.64% |
| Jul 31, 23 | -0.12 Increased by +63.64% | -0.19 Increased by +36.84% |
| May 4, 23 | -0.22 Increased by +18.52% | -0.21 Decreased by -6.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -23.02 M Decreased by -105.75% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -30.44 M Decreased by -82.29% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 1.16 M Decreased by -49.26% | -33.12 M Decreased by -36.60% | Decreased by -2.85 K% Decreased by -169.20% |
| Mar 31, 24 | 1.41 M Decreased by -35.87% | -27.34 M Decreased by -22.81% | Decreased by -1.94 K% Decreased by -91.50% |
| Dec 31, 23 | 8.88 M Increased by +780.60% | -11.19 M Increased by +71.49% | Decreased by -126.04% Decreased by -104.19% |
| Sep 30, 23 | 2.40 M Increased by +15.72% | -16.70 M Decreased by -0.88% | Decreased by -695.83% Increased by +12.82% |
| Jun 30, 23 | 2.29 M Increased by +49.64% | -24.24 M Decreased by -8.93% | Decreased by -1.06 K% Increased by +27.20% |
| Mar 31, 23 | 2.19 M Decreased by -13.83% | -22.27 M Decreased by -33.29% | Decreased by -1.01 K% Decreased by -54.67% |